THE POWER

After 30 years of proton pump inhibitors (PPIs), Voquezna (vonoprazan) introduces first-in-class acid suppression as the first potassium-competitive acid blocker available in the U.S. It’s approved for healing erosive esophagitis and, in combination with antibiotics, for H. pylori eradication through the Voquezna Triple Pak and Dual Pak. Phathom Pharmaceuticals tasked us with developing a campaign that elevates the Voquezna logo as a heroic force for both indications, highlighting its revolutionary role in acid suppression.

Creative Director